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Autochthonous hepatitis E is an emerging disease in indus-
trialized countries.1 Very recently, three cases have been described
in HIV-infected patients in Germany, France, and the USA.2–4
Another reported cause of acute hepatitis in the setting of HIV
infection is hepatitis B virus (HBV) reverse seroconversion and
reactivation in patients with HBV serology indicating past
infection.5,6 We present herein a case of concurrent hepatitis E
and HBV seroreversion in an HIV-1-infected patient.
A 54-year-old HIV-1-infected homosexual male presented in
June 2007 with jaundice and asthenia. His alanine aminotransfer-
ase (ALT) level was 373 IU/l, bilirubinemia was 52 mmol/l, and
prothrombin index (PI) was 56%. The CD4 count was 77 cells/mm3
and plasma HIV-1 RNA was 2.5 log10copies/ml. Tenofovir and
emtricitabine, two anti-HIV/HBV drugs, had been interrupted six
months earlier. HBV reactivation was diagnosed based on serum
HBV DNA-positivity (52 900 000 IU/ml; Cobas TaqMan Roche) and
hepatitis B surface antigen (HBsAg) seroreversion (Axsym Abbott
assay). Unexpectedly, concurrent hepatitis E was diagnosed based
on positive results on IgM anti-hepatitis E virus (HEV) antibody
testing (optical density ratios for IgG and IgM anti-HEV antibodies
were 0.20 and 10.4, respectively; EIAGen Adaltis kits) andHEV RNA
detection and sequencing from serum.7 Other major etiologies for
acute hepatitis were excluded. Retrospective analysis of a serum
sample collected in February 2007 did not detect HEV RNA or HBV
DNA, and showed HBsAg positivity, anti-hepatitis B core (HBc)
antibody positivity, and anti-hepatitis B surface (HBs) antibodies
<10 IU/l. The HEV was genotype 3. This genotype is the most
frequently found in autochthonous cases in Europe.1 The patient
did not report any recent travel abroad. The patient’s health
condition, initially poor, was worsening. Digestive B-lymphoma of
high-grade malignancy was diagnosed one month after hepatitis
onset. The HBV load showed a 3.8-log drop subsequent to
tenofovir/emtricitabine re-introduction. ALT normalized (7 IU/l),
but PI remained low (54%), and bilirubinemia increased up to
174 mmol/l. The patient died eight weeks after hepatitis onset. IgG
anti-HEV antibody testing just before death was still negative,
while HEV RNA was still positive in the serum.
In the present observation, HBV reactivationmight have hidden
concurrent hepatitis E if HEV testing had not been systematically
performed. Moreover, the HEV diagnosis may have been jeopar-
dized due to the persistent absence of anti-HEV IgG seroconver-
sion, which might have been related to the patient’s low CD4 cell
count. Indeed, such an atypical feature has previously been
described in severely immunosuppressed individuals.8,9 Hence,1201-9712/$36.00 – see front matter  2009 International Society for Infectious Disea
doi:10.1016/j.ijid.2009.04.007the present case prompts the inclusion of HEV RNA and IgM anti-
HEV antibody testing in routine diagnosis investigations of acute
hepatitis in HIV-infected patients, regardless of another identiﬁed
cause.
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